FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171876128> ?p ?o ?g. }

• W2171876128 endingPage "2269" @default.
• W2171876128 startingPage "2262" @default.
• W2171876128 abstract "In people with type 2 diabetes, a dipeptidyl peptidase-4 (DPP-4) inhibitor is one choice as second-line treatment after metformin, with basal insulin recommended as an alternative. We aimed to compare the efficacy, tolerability, and safety of insulin glargine and sitagliptin, a DPP-4 inhibitor, in patients whose disease was uncontrolled with metformin.In this comparative, parallel, randomised, open-label trial, metformin-treated people aged 35-70 years with glycated haemoglobin A(1c) (HbA(1c)) of 7-11%, diagnosis of type 2 diabetes for at least 6 months, and body-mass index of 25-45 kg/m(2) were recruited from 17 countries. Participants were randomly assigned (1:1) to 24-week treatment with insulin glargine (titrated from an initial subcutaneous dose of 0·2 units per kg bodyweight to attain fasting plasma glucose of 4·0-5·5 mmol/L) or sitagliptin (oral dose of 100 mg daily). Randomisation (via a central interactive voice response system) was by random sequence generation and was stratified by centre. Patients and investigators were not masked to treatment assignment. The primary outcome was change in HbA(1c) from baseline to study end. Efficacy analysis included all randomly assigned participants who had received at least one dose of study drug and had at least one on-treatment assessment of any primary or secondary efficacy variable. This trial is registered at ClinicalTrials.gov, NCT00751114.732 people were screened and 515 were randomly assigned to insulin glargine (n=250) or sitagliptin (n=265). At study end, adjusted mean reduction in HbA(1c) was greater for patients on insulin glargine (n=227; -1·72%, SE 0·06) than for those on sitagliptin (n=253; -1·13%, SE 0·06) with a mean difference of -0·59% (95% CI -0·77 to -0·42, p<0·0001). The estimated rate of all symptomatic hypoglycaemic episodes was greater with insulin glargine than with sitagliptin (4·21 [SE 0·54] vs 0·50 [SE 0·09] events per patient-year; p<0·0001). Severe hypoglycaemia occurred in only three (1%) patients on insulin glargine and one (<1%) on sitagliptin. 15 (6%) of patients on insulin glargine versus eight (3%) on sitagliptin had at least one serious treatment-emergent adverse event.Our results support the option of addition of basal insulin in patients with type 2 diabetes inadequately controlled by metformin. Long-term benefits might be expected from the achievement of optimum glycaemic control early in the course of the disease.Sanofi." @default.
• W2171876128 created "2016-06-24" @default.
• W2171876128 creator A5013052910 @default.
• W2171876128 creator A5014166773 @default.
• W2171876128 creator A5030986164 @default.
• W2171876128 creator A5034671525 @default.
• W2171876128 creator A5041274229 @default.
• W2171876128 creator A5062386238 @default.
• W2171876128 creator A5078134786 @default.
• W2171876128 creator A5088504435 @default.
• W2171876128 creator A5091832416 @default.
• W2171876128 date "2012-06-01" @default.
• W2171876128 modified "2023-10-16" @default.
• W2171876128 title "Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial" @default.
• W2171876128 cites W1980024665 @default.
• W2171876128 cites W1983269691 @default.
• W2171876128 cites W2007003907 @default.
• W2171876128 cites W2018192866 @default.
• W2171876128 cites W2041901656 @default.
• W2171876128 cites W2055960111 @default.
• W2171876128 cites W2074343527 @default.
• W2171876128 cites W2099092932 @default.
• W2171876128 cites W2100862440 @default.
• W2171876128 cites W2102076191 @default.
• W2171876128 cites W2115653936 @default.
• W2171876128 cites W2126781806 @default.
• W2171876128 cites W2127521907 @default.
• W2171876128 cites W2131505599 @default.
• W2171876128 cites W2139171405 @default.
• W2171876128 cites W2139562487 @default.
• W2171876128 cites W2144125787 @default.
• W2171876128 cites W2159851358 @default.
• W2171876128 cites W2162708888 @default.
• W2171876128 cites W2171294019 @default.
• W2171876128 cites W2171512247 @default.
• W2171876128 cites W2188846692 @default.
• W2171876128 cites W2337454357 @default.
• W2171876128 doi "https://doi.org/10.1016/s0140-6736(12)60439-5" @default.
• W2171876128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22683131" @default.
• W2171876128 hasPublicationYear "2012" @default.
• W2171876128 type Work @default.
• W2171876128 sameAs 2171876128 @default.
• W2171876128 citedByCount "99" @default.
• W2171876128 countsByYear W21718761282012 @default.
• W2171876128 countsByYear W21718761282013 @default.
• W2171876128 countsByYear W21718761282014 @default.
• W2171876128 countsByYear W21718761282015 @default.
• W2171876128 countsByYear W21718761282016 @default.
• W2171876128 countsByYear W21718761282017 @default.
• W2171876128 countsByYear W21718761282018 @default.
• W2171876128 countsByYear W21718761282019 @default.
• W2171876128 countsByYear W21718761282020 @default.
• W2171876128 countsByYear W21718761282021 @default.
• W2171876128 countsByYear W21718761282022 @default.
• W2171876128 crossrefType "journal-article" @default.
• W2171876128 hasAuthorship W2171876128A5013052910 @default.
• W2171876128 hasAuthorship W2171876128A5014166773 @default.
• W2171876128 hasAuthorship W2171876128A5030986164 @default.
• W2171876128 hasAuthorship W2171876128A5034671525 @default.
• W2171876128 hasAuthorship W2171876128A5041274229 @default.
• W2171876128 hasAuthorship W2171876128A5062386238 @default.
• W2171876128 hasAuthorship W2171876128A5078134786 @default.
• W2171876128 hasAuthorship W2171876128A5088504435 @default.
• W2171876128 hasAuthorship W2171876128A5091832416 @default.
• W2171876128 hasConcept C126322002 @default.
• W2171876128 hasConcept C134018914 @default.
• W2171876128 hasConcept C197934379 @default.
• W2171876128 hasConcept C2777180221 @default.
• W2171876128 hasConcept C2778375690 @default.
• W2171876128 hasConcept C2779284873 @default.
• W2171876128 hasConcept C2779306644 @default.
• W2171876128 hasConcept C2779920387 @default.
• W2171876128 hasConcept C2780323712 @default.
• W2171876128 hasConcept C2780668416 @default.
• W2171876128 hasConcept C2910068830 @default.
• W2171876128 hasConcept C555293320 @default.
• W2171876128 hasConcept C71924100 @default.
• W2171876128 hasConceptScore W2171876128C126322002 @default.
• W2171876128 hasConceptScore W2171876128C134018914 @default.
• W2171876128 hasConceptScore W2171876128C197934379 @default.
• W2171876128 hasConceptScore W2171876128C2777180221 @default.
• W2171876128 hasConceptScore W2171876128C2778375690 @default.
• W2171876128 hasConceptScore W2171876128C2779284873 @default.
• W2171876128 hasConceptScore W2171876128C2779306644 @default.
• W2171876128 hasConceptScore W2171876128C2779920387 @default.
• W2171876128 hasConceptScore W2171876128C2780323712 @default.
• W2171876128 hasConceptScore W2171876128C2780668416 @default.
• W2171876128 hasConceptScore W2171876128C2910068830 @default.
• W2171876128 hasConceptScore W2171876128C555293320 @default.
• W2171876128 hasConceptScore W2171876128C71924100 @default.
• W2171876128 hasIssue "9833" @default.
• W2171876128 hasLocation W21718761281 @default.
• W2171876128 hasLocation W21718761282 @default.
• W2171876128 hasOpenAccess W2171876128 @default.
• W2171876128 hasPrimaryLocation W21718761281 @default.
• W2171876128 hasRelatedWork W1983641721 @default.
• W2171876128 hasRelatedWork W2033313326 @default.
• W2171876128 hasRelatedWork W2095227308 @default.

• next